SCHEMBL2898490

SCHEMBL2898490

CC(c1ccccn1)n1c(=O)c(O)c2n(c1=O)CCN(Cc1ccc(F)cc1)C2=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.41
GRM2 Q14416 1/20 0.41
ALDH1A1 P00352 6/20 0.39
LMNA P02545 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
PKM P14618 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SCD O00767 1/20 0.37
TP53 P04637 2/20 0.36
CYP2D6 P10635 1/20 0.36
HRH3 Q9Y5N1 1/20 0.36
CACNA2D1 P54289 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 2/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
CLPP Q16740 1/20 0.35
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2899665 0.81 KCNH2 (0.41) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2898100 0.79 MEN1 (0.40) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2899829 0.78 HRH3 (0.47) ALDH1A1LMNAPKMNPSR1HRH3
SCHEMBL2898168 0.77 KCNH2 (0.41) KCNH2GRM2ALDH1A1LMNATP53
SCHEMBL2890924 0.76 KCNH2 (0.45) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL4145906 0.74 TACR1 (0.47) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2891980 0.74 KCNH2 (0.41) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2895650 0.73 MAOB (0.38) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2898871 0.73 HDAC1 (0.40) PKMCYP2D6HRH3MEN1KMT2A
SCHEMBL2891898 0.72 KCNH2 (0.42) KCNH2GRM2ALDH1A1TP53CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP KCNH2 3441/4885GRM2 4668/4885ALDH1A1 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.